Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Aug 24, 2011


Bruce Taillon, formerly the director of healthcare business development at Roche's 454 Life Sciences division, is now the head of global technology business development at Enzo Life Science. While at 454, Taillon helped develop the company's next-generation sequencing platforms, including for its potential use in diagnostic assays. He also has experience leading R&D teams in the areas of genomics, proteomics, and drug development.

Pathogenica founder and CEO Yemi Adesokan has been named by MIT's Technology Review as one of its top innovators under the age of 35, for his work on developing sequencing-based diagnostic tests that can identify pathogens. His company is aiming to launch an FDA-approved test to diagnose HPV by 2012, and is also working on tests that can monitor drug resistance in HIV patients (CSN 8/17/2011). Previously, Adesokan was a research fellow in genetics at Harvard Medical School. He holds a PhD in chemistry from the University of California, Irvine.

The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.